FDA chief Scott Gottlieb steps down after nearly 2 years
(AP Photo/J. Scott Applewhite, File) In this Wednesday, April 5, 2017, file photo, Dr. Scott Gottlieb speaks during his confirmation hearing before a Senate committee, in Washington, as President Donald Trump's nominee to head the Food and Drug Administration. Gottlieb is stepping down after nearly two years leading the agency’s response to a host of public health challenges, including the opioid epidemic, rising drug prices and underage vaping.
Washington • Food and Drug Administration Commissioner Scott Gottlieb is stepping down after nearly two years leading the agency’s response to a host of public health challenges, including the opioid epidemic, rising drug prices and underage vaping.
Health and Human Services Secretary Alex Azar announced Gottlieb's planned resignation in a statement Tuesday.
President Donald Trump tapped Gottlieb in 2017 to "cut red tape" at the FDA.
Gottlieb bucked expectations by pushing the agency to expand its authorities in several key ways, including an unprecedented effort to make cigarettes less addictive by requiring lower nicotine levels.
More recently, Gottlieb has been criticized for not acting sooner to address an explosion in teenage use of e-cigarettes.
For over 150 years, The Salt Lake Tribune has been Utah’s independent news source. Our reporters work tirelessly to uncover the stories that matter most to Utahns, from unraveling the complexities of court rulings to allowing tax payers to see where and how their hard earned dollars are being spent. This critical work wouldn’t be possible without people like you—individuals who understand the importance of local, independent journalism. As a nonprofit newsroom, every subscription and every donation fuels our mission, supporting the in-depth reporting that shines a light on the is sues shaping Utah today.
You can help power this work.
Donate to the newsroom now. The Salt Lake Tribune, Inc. is a 501(c)(3) public charity and contributions are tax deductible